CTLA4 and cancer: Since 2010, cancer immunotherapy drugs including CTLA4 (cytotoxic T-lymphocyte-associated protein 4) inhibitors, PD-1 (programmed cell death protein 1) inhibitors, PD-L1 (programmed cell death ligand 1) inhibitors, and CAR (chimeric antigen receptor)-T cell therapy have received a lot of attention.